Synergy of Hydeal-D^® and Hyaluronic Acid for Protecting and Restoring Urothelium: In Vitro Characterization

• Main Authors: Marco Ruggeri (Author), Mauro Pavan (Author), Matteo Soato (Author), Susi Panfilo (Author), Carlo Barbera (Author), Devis Galesso (Author), Dalila Miele (Author), Silvia Rossi (Author), Alba Di Lucia (Author), Franca Ferrari (Author), Giuseppina Sandri (Author)
• Format: Book
• Published: MDPI AG, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Interstitial cystitis (IC) or painful bladder syndrome is a chronic dysfunction due to an inflammatory condition, characterized by bladder pain and urinary frequency. Currently, no gold standard therapy is available since IC does not respond to conventional ones. Given these premises, the aim of this work was the in vitro characterization of biological properties (mucoadhesion and anti-inflammatory activity) of a commercial product (HydealCyst-HydC) based on hyaluronic acid (HA) and the benzyl ester of HA (Hydeal-D^®) intended for bladder instillation to restore and/or protect the urothelial layer of glycosamino glycans (GAGs). The in vitro characterization demonstrated that an interaction product is formed between HA and Hydeal-D^® that has a role in the rheological behavior and mucoadhesive properties. HA was identified as a key component to form the mucoadhesive joint, while the interaction of HA with Hydeal-D^® improved polysaccharide stability and prolonged the activity <i>ex vivo</i>. Moreover, HydC is cytocompatible with urothelial cells (HTB-4) and possesses an anti-inflammatory effect towards these cells by decreasing the secretion of IL-6 and IL-8, which were both increased in patients with IC, and by increasing the secretion of sulfated GAGs. These two findings, along with the resilience properties of the formulation due to mucoadhesion, suggest the active role of HydC in protecting and restoring urothelium homeostasis.

Item Description

10.3390/pharmaceutics13091450
1999-4923